Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of BROVANA® (arformoterol tartrate) Inhalation Solution for your patients

ORDER YOUR SAMPLES NOW

REQUEST A THERAPEUTIC SPECIALIST

Need support for your patients? Ask Sunovion Answers for information about BROVANA® (arformoterol tartrate)

 

A dedicated team is available between 8 AM and 8 PM ET, Monday through Friday, to answer calls at 1-844-276-8262

LEARN MORE

REQUEST A THERAPEUTIC SPECIALIST

Most Viewed

Conference Calendar

Mark your calendar:

ATS 2018

May 18 - May 23 | San Diego, CA

Find more details below ▼

 

 

We can’t wait to meet you at the next conference or convention that Sunovion will be attending in 2018. 

 

January 1-31

 

February 1-28

FEB 8-11

Pri-Med South

VISIT CONVENTION WEBSITE

Broward County Convention Center
1950 Eisenhower Blvd
Fort Lauderdale, FL 33316

Exhibit Details

Dates:
February 9-11

Hours:

Friday, February 9
8:30 AM  –  4:30 PM

Saturday, February 10
9:30 AM  –  4:15 PM

Sunday, February 11
9:00 AM  –  1:15 PM

 

March 1-31

MAR 22-25

AMDA Annual Conference 2018

The Society for Post-Acute and Long-Term Care Medicine

VISIT CONVENTION WEBSITE

Gaylord Texan Resort and Convention Center
1501 Gaylord Trail
Grapevine, TX 76051

Exhibit Details

Dates:
March 22-23

Hours:
Thursday, March 22
11:00 AM  –  7:00 PM

Friday, March 23
10:30 AM  –  3:25 PM

 

April 1-30

APR 19-21

ACP 2018

The American College of Physicians

VISIT CONVENTION WEBSITE

Ernest N. Morial Convention Center
900 Convention Center Blvd
New Orleans, LA 70130

Exhibit Details

Dates:
April 19-21

Hours:
Thursday, April 19
10:00 AM  –  4:30 PM

Friday, April 20
10:00 AM  –  4:30 PM

Saturday, April 21
10:00 AM  –  2:30 PM

APR 30-2

Spring Hospital Pharmacy Conference

VISIT CONVENTION WEBSITE

Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, GA 30303

Exhibit Details

Date:
April 30

Hours:
Monday, April 30
12:00 PM  –  4:00 PM

 

May 1-31

May 16-18

Pri-Med Southwest

VISIT CONVENTION WEBSITE

George R. Brown Convention Center
1001 Avenida De Las Americas
Houston, TX 77010

Exhibit Details

Dates:
May 16-18

May 18-23

ATS 2018

American Thoracic Society

VISIT CONVENTION WEBSITE

San Diego Convention Center
111 W Harbor Dr
San Diego, CA 92101

Exhibit Details

Dates:
May 20-22

May 30-2

Pri-Med West

VISIT CONVENTION WEBSITE

Anaheim Convention Center
800 W Katella Ave
Anaheim, CA 92802

Exhibit Details

Dates:
June 1-2

 

June 1-30

 

July 1-31

 

August 1-31

 

September 1-30

Sep 6-9

Eastern Pulmonary Conference (EPC)

Jointly Provided by the American College of Allergy, Asthma, & Immunology (ACAAI) and the Eastern Pulmonary Conference (EPC)

VISIT CONVENTION WEBSITE

The Breakers Palm Beach
1 South County Road
Palm Beach, FL  33480

Exhibit Details

Dates:
September 7-8

 

October 1-31

OCT 1-3

Fall Hospital Pharmacy Conference

VISIT CONVENTION WEBSITE

Westin Bonaventure
404 S Figueroa St
Los Angeles, CA 90071

Exhibit Details

Date:
October 1

Hours:
Monday, October 1
12:00 PM  –  4:00 PM

OCT 6-10

CHEST 2018

American College of Chest Physicians

VISIT CONVENTION WEBSITE

Henry B. Gonzalez Convention Center
900 E Market St
San Antonio, TX 78205

Exhibit Details

Dates:
October 8-10

OCT 10-13

Pri-Med Midwest

VISIT CONVENTION WEBSITE

Donald E. Stephens Convention Center
5555 N River Rd
Rosemont, IL 60018

Exhibit Details

Dates:
October 11-13

 

 

November 1-30

 

December 1-31

DEC 2-6

ASHP 2018 Midyear Clinical Meeting

American Society of Health-System Pharmacists

VISIT CONVENTION WEBSITE

Anaheim, CA  
Location details coming soon

Exhibit Details

Dates:
December 3-5

DEC 4-7

AARC Congress 2018

American Association for Respiratory Care

VISIT CONVENTION WEBSITE

Las Vegas, NV
Location details coming soon

Exhibit Details

Dates:
December 5-7

DEC 6-9

Pri-Med East

VISIT CONVENTION WEBSITE

John B. Hynes Veterans Memorial Convention Center
900 Boylston St
Boston, MA 02115

Exhibit Details

Dates:
December 7-9

Important Safety Information & Indication

Important Safety Information

WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABAs, including arformoterol, the active ingredient in BROVANA.

The safety and efficacy of BROVANA in patients with asthma have not been established. BROVANA is not indicated for the treatment of asthma.


All LABAs, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication; BROVANA is also contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any of the ingredients. 

BROVANA should not be initiated in patients with acutely deteriorating COPD or potentially life-threatening episodes of COPD, or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

BROVANA should not be used more often, at higher doses than recommended, or in conjunction with other medications containing LABAs as an overdose may result. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using BROVANA should not use another medicine containing a LABA for any reason.

Immediate hypersensitivity reactions may occur with BROVANA. If signs occur, discontinue immediately and institute alternative therapy.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Beta2-adrenergic agonists may produce significant hypokalemia in some patients.

As with other beta2-agonists, BROVANA, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because these agents may potentiate the action of adrenergic agonists on the cardiovascular system.

As with other beta2-agonists, BROVANA should be used with caution in patients treated with additional adrenergic drugs, non-potassium-sparing diuretics, and beta-blockers.

BROVANA, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

BROVANA should not be swallowed as the intended effects on the lungs will not be obtained.  BROVANA is only for oral inhalation via a standard jet nebulizer connected to an air compressor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see the full Prescribing Information including BOXED WARNING, and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution, at www.sunovionprofile.com/brovana.

Indication

BROVANA® (arformoterol tartrate) Inhalation Solution is a long-acting beta2 -adrenergic agonist (LABA) indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. BROVANA is for use by nebulization only.

Important limitations: BROVANA is not indicated to treat acute deteriorations of COPD and is not indicated to treat asthma.